These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 7673023

  • 1. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
    Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L.
    Int J Radiat Oncol Biol Phys; 1995 Sep 30; 33(2):357-64. PubMed ID: 7673023
    [Abstract] [Full Text] [Related]

  • 2. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K, Wilson CB.
    Int J Radiat Oncol Biol Phys; 1995 Apr 30; 32(1):75-83. PubMed ID: 7721642
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.
    Int J Radiat Oncol Biol Phys; 2002 May 01; 53(1):58-66. PubMed ID: 12007942
    [Abstract] [Full Text] [Related]

  • 4. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR.
    Clin Cancer Res; 2000 Oct 01; 6(10):3878-84. PubMed ID: 11051233
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA.
    Int J Radiat Oncol Biol Phys; 1999 Aug 01; 45(1):127-35. PubMed ID: 10477016
    [Abstract] [Full Text] [Related]

  • 6. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, Mutani R.
    Cancer; 2004 Feb 15; 100(4):807-13. PubMed ID: 14770438
    [Abstract] [Full Text] [Related]

  • 7. Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
    Loeffler JS, Shrieve DC, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1995 Sep 30; 33(2):531-3. PubMed ID: 7673044
    [No Abstract] [Full Text] [Related]

  • 8. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1147-52. PubMed ID: 15001257
    [Abstract] [Full Text] [Related]

  • 9. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST.
    J Neurosurg; 2011 Aug 15; 115(2):220-9. PubMed ID: 21548745
    [Abstract] [Full Text] [Related]

  • 10. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
    Afra D, Sipos L, Vitanovics D.
    Ideggyogy Sz; 2002 Jan 20; 55(1-2):38-44. PubMed ID: 12122942
    [Abstract] [Full Text] [Related]

  • 11. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
    Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2003 Apr 15; 21(8):1485-91. PubMed ID: 12697871
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
    Phillips TL, Levin VA, Ahn DK, Gutin PH, Davis RL, Wilson CB, Prados MD, Wara WM, Flam MS.
    Int J Radiat Oncol Biol Phys; 1991 Aug 15; 21(3):709-14. PubMed ID: 1651306
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Levin VA, Lamborn K, Wara W, Davis R, Edwards M, Rabbitt J, Malec M, Prados MD.
    Neuro Oncol; 2000 Jan 15; 2(1):22-8. PubMed ID: 11302250
    [Abstract] [Full Text] [Related]

  • 14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 15. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
    Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK.
    Oncol Rep; 2007 Jun 15; 17(6):1359-64. PubMed ID: 17487391
    [Abstract] [Full Text] [Related]

  • 16. [The effect of extent of tumor resection on the outcome of combined therapy in patients with glioblastoma multiforme].
    Jeremić B, Grulicić D, Samardzić M, Antunović V, Joksimović M, Djurić Lj, Milicić B, Nikolić N.
    Srp Arh Celok Lek; 1997 Jun 15; 125(3-4):93-8. PubMed ID: 9221525
    [Abstract] [Full Text] [Related]

  • 17. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA.
    Int J Radiat Oncol Biol Phys; 2001 Jan 01; 49(1):71-7. PubMed ID: 11163499
    [Abstract] [Full Text] [Related]

  • 18. PCV chemotherapy for recurrent glioblastoma.
    Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M.
    Neurology; 2006 Feb 28; 66(4):587-9. PubMed ID: 16505319
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
    Liau CT, Wei KC, Tseng CK, Jung SM.
    Chang Gung Med J; 2005 Jan 28; 28(1):16-23. PubMed ID: 15804144
    [Abstract] [Full Text] [Related]

  • 20. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kölbl O, Flentje M.
    BMC Cancer; 2006 Oct 18; 6():247. PubMed ID: 17049083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.